Potential treatment of COVID-19 by inhibitors of human dihydroorotate dehydrogenase.
10.1007/s13238-020-00769-9
- Author:
Yechun XU
1
;
Hualiang JIANG
2
Author Information
1. CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
2. CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. hljiang@simm.ac.cn.
- Publication Type:Journal Article
- MeSH:
Animals;
Betacoronavirus;
Coronavirus Infections;
drug therapy;
Drug Discovery;
Drug Evaluation, Preclinical;
Enzyme Inhibitors;
therapeutic use;
Humans;
Mice;
Molecular Structure;
Orthomyxoviridae Infections;
drug therapy;
Oseltamivir;
therapeutic use;
Oxidoreductases;
antagonists & inhibitors;
Pandemics;
Pneumonia, Viral;
drug therapy;
Pyrimidines;
biosynthesis
- From:
Protein & Cell
2020;11(10):699-702
- CountryChina
- Language:English
